Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor
By A Mystery Man Writer
Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.
Cancer Therapy Advisor September/October 2017 Issue by Haymarket
Lapatinib and lapatinib plus trastuzumab therapy versus
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies
Lapatinib and lapatinib plus trastuzumab therapy versus
Lapatinib and lapatinib plus trastuzumab therapy versus
Tyrosine kinase inhibitors and human epidermal growth factor
Lapatinib and lapatinib plus trastuzumab therapy versus
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies
A phase II study of lapatinib and bevacizumab as treatment for
Lapatinib and lapatinib plus trastuzumab therapy versus